Physician profile
Peter C Miller
NPI 1043430606
$3,258.19
in general payments reported to CMS, 2019-2025
32 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,032 · 2020: $252 · 2021: $253 · 2022: $800 · 2023: $453 · 2024: $243 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $920.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $664.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $334.60 | 2019-2025 | Evenity, Otezla, Repatha |
| Abbvie INC. | $293.40 | 2019-2024 | |
| Glaxosmithkline, LLC. | $276.89 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $231.15 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $207.11 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.32 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $120.23 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $112.58 | 2019-2022 | |
| Lilly USA, LLC | $82.95 | 2019-2023 | Emgality, Reyvow |
| Bayer Healthcare Pharmaceuticals INC. | $76.24 | 2021-2023 | |
| Sanofi Pasteur INC. | $74.96 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $60.55 | 2019-2025 | Eliquis |
| Astellas Pharma US INC | $59.49 | 2019-2021 | |
| Radius Health, INC. | $50.42 | 2022-2025 | Tymlos |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $47.58 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $47.03 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $39.85 | 2022-2023 | Livalo, Seglentis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.78 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.16 | 2019 | |
| Mylan Specialty L.P. | $32.60 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.79 | 2019 | |
| Exact Sciences Corporation | $30.42 | 2023 | Cologuard Collection Kit |
| Johnson & Johnson Vision Care, INC. | $30.27 | 2025 | |
| Amarin Pharma, INC. | $30.25 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $27.21 | 2019-2022 | |
| Halozyme INC | $21.73 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $19.16 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.87 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.52 | 2019 | |
| Averitas Pharma INC. | $13.37 | 2023 | Qutenza |
| Gilead Sciences, INC. | $13.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.